Search results for " Immunology and Allergy"

showing 10 items of 141 documents

The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

2018

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Italian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their paren…

GerontologyMaleParentsPatient Reported Outcome MeasurePsychometricsHealth StatusArthritisJuvenilePredictive Value of TestHealth StatuDisability Evaluation0302 clinical medicineMedicineImmunology and AllergyFunctional abilityAge of OnsetChildJAMARPatientPrognosisDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Adolescent; Age of Onset; Arthritis Juvenile; Case-Control Studies; Child; Child Preschool; Cultural Characteristics; Female; Health Status; Humans; Italy; Male; Parents; Patients; Predictive Value of Tests; Prognosis; Psychometrics; Quality of Life; Reproducibility of Results; Rheumatology; Translating; Disability Evaluation; Patient Reported Outcome MeasuresCultural CharacteristicSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyChild PreschoolPredictive value of testsFemaleCase-Control StudiePsychometricHumanmedicine.medical_specialtyDisease statusAdolescentPatientsPsychometricsPrognosiImmunologyReproducibility of ResultDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Rheumatology; Immunology and Allergy; Immunology03 medical and health sciencesJuvenile idiopathic arthritiQuality of life (healthcare)RheumatologyDisease status Functional ability Health Related Quality of Life JAMAR Juvenile idiopathic arthritis Adolescent Age of Onset Arthritis Juvenile Case-Control Studies Child Child Preschool Cultural Characteristics Female Health Status Humans Italy Male Parents Patients Predictive Value of Tests Prognosis Psychometrics Quality of Life Reproducibility of Results Rheumatology Translating Disability Evaluation Patient Reported Outcome MeasuresPredictive Value of Tests030225 pediatricsInternal medicineJuvenileHumansValidation StudiesPatient Reported Outcome MeasuresDisease statuPreschool030203 arthritis & rheumatologyCultural Characteristicsbusiness.industryArthritisReproducibility of ResultsHealth Related Quality of LifeTranslatingJuvenile idiopathic arthritismedicine.diseaseFunctional abilityArthritis JuvenileRheumatologyParentCase-Control StudiesQuality of LifeAge of onsetbusiness
researchProduct

Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study

2017

This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox re…

Lung DiseasesMaleOncologylung diseaseAntifungal AgentsSkin Neoplasmsmedicine.medical_treatment030230 surgeryTHERAPY030207 dermatology & venereal diseases0302 clinical medicinelung transplantation/pulmonologypatient safetyEPIDEMIOLOGYMedicineImmunology and AllergyPharmacology (medical)malignant [complication]RISKHazard ratioImmunosuppressionMiddle AgedPrognosisinfection and infectious agents - fungalPRACTICE GUIDELINEScomplication: malignantCarcinoma Squamous Cellantifungal [antibiotic]FemaleLung Transplantationmedicine.drugCohort studyAdultmedicine.medical_specialtyAdolescentinfectious diseaseSOCIETYANTIFUNGAL PROPHYLAXISclinical research/practiceArticleYoung Adult03 medical and health sciencesantibiotic: antifungal; clinical research/practice; complication: malignant; health services and outcomes research; infection and infectious agents - fungal; infectious disease; lung disease; lung transplantation/pulmonology; patient safety; Immunology and Allergy; Transplantation; Pharmacology (medical)LONG-TERM VORICONAZOLEInternal medicineHumansLung transplantationEXPOSUREAgedRetrospective StudiesVoriconazoleTransplantationSKIN-CANCERbusiness.industryProportional hazards modelRetrospective cohort studyantibiotic: antifungalhealth services and outcomes researchTransplant RecipientsSurgeryTransplantationRECIPIENTSVoriconazolebusinessFollow-Up Studies
researchProduct

Pathological significance and prognostic value of surfactant protein D in cancer

2018

Surfactant protein D (SP-D) is a pattern recognition molecule belonging to the Collectin (collagen-containing C-type lectin) family that has pulmonary as well as extra-pulmonary existence. In the lungs, it is a well-established opsonin that can agglutinate a range of microbes, and enhance their clearance via phagocytosis and super-oxidative burst. It can interfere with allergen–IgE interaction and suppress basophil and mast cell activation. However, it is now becoming evident that SP-D is likely to be an innate immune surveillance molecule against tumor development. SP-D has been shown to induce apoptosis in sensitized eosinophils derived from allergic patients and a leukemic cell line via …

Male0301 basic medicineLung NeoplasmsDatasets as Topic0302 clinical medicineEpidermal growth factorNeoplasmsImmunology and AllergyRNA NeoplasmOriginal ResearchCancerOvarian NeoplasmsInnate immunitySurfactant protein DBioinformatics analysiPrognosisPulmonary Surfactant-Associated Protein DImmunohistochemistryTumor microenvironment030220 oncology & carcinogenesisAdenocarcinomaFemaleCancersBreast NeoplasmHumanlcsh:Immunologic diseases. AllergyPrognosiImmunologyBreast NeoplasmsBiology03 medical and health sciencesImmune systemBioinformatics analysisStomach NeoplasmsStomach NeoplasmBiomarkers TumormedicineHumansComputer SimulationLung cancerTumor microenvironmentOvarian NeoplasmComputational BiologySurfactant protein DCancermedicine.diseaseSurvival AnalysisLung NeoplasmImmune surveillance030104 developmental biologyCancer researchNeoplasmBioinformatics analysis; Cancers; Immune surveillance; Immunohistochemistry; Innate immunity; Surfactant protein D; Tumor microenvironment; Immunology and Allergy; Immunologylcsh:RC581-607Ovarian cancer
researchProduct

Has VZV epidemiology changed in Italy? Results of a seroprevalence study

2017

The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era. During 2013–2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations were collected in collaboration with at least one laboratory/center for each region, following the approval of the Ethics Committee. Data were stratified by sex and age. All samples were processed in a national reference laboratory by an immunoassay with high sensitivity and specificity. Statutory notifications, national hospital discharge database and mortality data related to V…

Male0301 basic medicinePediatricsCross-sectional studySeroprevalenceSettore MED/42 - Igiene Generale E ApplicataAntibodies Viralmedicine.disease_causeChickenpox0302 clinical medicineChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Chickenpox; Child; Child Preschool; Cross-Sectional Studies; Female; Humans; Infant; Infant Newborn; Italy; Male; Middle Aged; Seroepidemiologic Studies; Young Adult; Immunology and Allergy; Immunology; PharmacologySeroepidemiologic StudiesEpidemiology80 and overImmunology and AllergyAge FactorViral030212 general & internal medicineYoung adultChildskin and connective tissue diseasesAged 80 and overSurveillanceChickenpoxVaricella-Zoster ViruAge FactorsMiddle AgedResearch PapersItalyChild PreschoolFemaleChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Immunology and Allergy; Immunology; PharmacologyHumanAdultmedicine.medical_specialtyAdolescent030106 microbiologyImmunologyAntibodiesNOYoung Adult03 medical and health sciencesChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster VirusmedicineHumansSeroprevalencePreschoolAgedCross-Sectional StudiePharmacologybusiness.industrySeroepidemiologic StudieInfant NewbornVaricella zoster virusInfantSeroepidemiologic StudiesNewbornmedicine.diseaseVaricella-Zoster VirusCross-Sectional StudiesImmunizationImmunizationsense organsChickenpox Immunization Seroprevalence Surveillance Varicella-Zoster Virus Immunology and Allergy Immunology Pharmacologybusiness
researchProduct

Chaperone patterns in vernal keratoconjunctivitis are distinctive of cell and Hsp type and are modified by inflammatory stimuli

2016

Background Vernal keratoconjunctivitis (VKC) is a severe ocular allergy with pathogenic mechanism poorly understood and no efficacious treatment. The aims of the study were to determine quantities and distribution of Hsp chaperones in the conjunctiva of VKC patients and assess their levels in conjunctival epithelial and fibroblast cultures exposed to inflammatory stimuli. Methods Hsp10, Hsp27, Hsp40, Hsp60, Hsp70, Hsp90, Hsp105, and Hsp110 were determined in conjunctiva biopsies from nine patients and nine healthy age-matched normal subjects, using immunomorphology and qPCR. Conjunctival epithelial cells and fibroblasts were cultured and stimulated with IL-1β, histamine, IL-4, TNF-α, or UV-…

Male0301 basic medicinequantitative Hsp patternschemistry.chemical_compoundChaperonesHspchaperoneImmunology and AllergyChildCells CulturedHeat-Shock ProteinsConjunctivitis AllergicCulturedbiologyCD68conjunctival cells Hspconjunctival cellsImmunohistochemistrychaperones; conjunctival cells Hsp; quantitative Hsp patterns; vernal keratoconjunctivitis; Immunology; Immunology and Allergymedicine.anatomical_structureFemaleHistaminequantitative Hsp patternConjunctivaAdolescentCellsImmunologyTryptasevernal keratoconjunctivitiNO03 medical and health sciencesAllergicImmune systemHsp27Heat shock proteinmedicineHumansvernal keratoconjunctivitischaperones; conjunctival cells Hsp; quantitative Hsp patterns; vernal keratoconjunctivitis; Adolescent; Cells Cultured; Child; Conjunctivitis Allergic; Epithelial Cells; Female; Fibroblasts; Heat-Shock Proteins; Humans; Immunohistochemistry; Male; Molecular Chaperones; Immunology and Allergy; ImmunologyEpithelial CellsFibroblastsConjunctivitismedicine.diseaseeye diseases030104 developmental biologychemistryImmunologybiology.proteinChaperones; conjunctival cells Hsp; quantitative Hsp patterns; vernal keratoconjunctivitisVernal keratoconjunctivitisMolecular Chaperones
researchProduct

Trends of influenza B during the 2010–2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisatio…

2017

Influenza A and B viruses are responsible for respiratory infections, representing globally seasonal threats to human health. The 2 viral types often co-circulate and influenza B plays an important role in the spread of infection. A 6-year retrospective surveillance study was conducted between 2010 and 2016 in 2 large administrative regions of Italy, located in the north (Liguria) and in the south (Sicily) of the country, to describe the burden and epidemiology of both B/Victoria and B/Yamagata lineages in different healthcare settings. Influenza B viruses were detected in 5 of 6 seasonal outbreaks, exceeding influenza A during the season 2012–2013. Most of influenza B infections were found…

Male0301 basic medicinevirusesInfluenza B viruDisease OutbreaksHuman health0302 clinical medicineRetrospective StudieEpidemiologyImmunology and Allergy030212 general & internal medicinehospitalChildSicilyB/Victoriaeducation.field_of_studyDisease OutbreakVaccinationvirus diseasesB/Victoria; B/Yamagata; community; hospital; Influenza type B; lineage; vaccine-mismatch; Immunology and Allergy; Immunology; Pharmacologyvaccine-mismatchInfluenza type BInfluenza A viruInfluenza A virusInfluenza VaccinesChild PreschoolcommunityCommunity settingFemaleSeasonsInfluenza VaccineHumanResearch Papermedicine.medical_specialty030106 microbiologyImmunologyPopulationEpidemic03 medical and health sciencesInfluenza HumanmedicineHumansEpidemicseducationRetrospective StudiesPharmacologyInfluenza immunisationbusiness.industryOutbreakInfluenza aVirologyInfluenza B virusVaccine mismatchSeasonbusinessB/YamagatalineageDemographyHuman Vaccines & Immunotherapeutics
researchProduct

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

2016

BACKGROUND: The consensus documents published to date on hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) have focused on adult patients. Many of the previous recommendations have not been adapted to pediatric patients. We intended to produce consensus recommendations for the diagnosis and management of pediatric patients with C1-INH-HAE.METHODS: During an expert panel meeting that took place during the 9th C1 Inhibitor Deficiency Workshop in Budapest, 2015 (www.haenet.hu), pediatric data were presented and discussed and a consensus was developed by voting.RESULTS: The symptoms of C1-INH-HAE often present in childhood. Differential diagnosis can be difficult as abdominal pain…

MaleAbdominal painPediatricsdiagnosisComorbidityDiseaseSeverity of Illness IndexEcallantide0302 clinical medicineRisk FactorsDiagnosisImmunology and Allergyheterocyclic compounds030212 general & internal medicineHereditary angioedemaPediatricHereditary Angioedema Types I and IIAge FactorsDisease ManagementCombined Modality TherapyImmunodeficienciesManagementHereditary angioedemaFemaleOriginal ArticleSymptom Assessmentmedicine.symptommanagementAlgorithmsmedicine.drugmedicine.medical_specialtyC1 inhibitor deficiencyImmunology03 medical and health sciencesMeta-Analysis as TopicmedicineHumansMucous MembraneAdult patientsbusiness.industryOriginal ArticlesC1 inhibitor deficiency; Diagnosis; Hereditary angioedema; Management; Pediatric; Immunology and Allergy; Immunologybacterial infections and mycosesmedicine.diseasehereditary angioedemarespiratory tract diseasesClinical trialpediatric030228 respiratory systemC1 inhibitor deficiencyDifferential diagnosisbusinessBiomarkers
researchProduct

Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey

2016

Background The aim was to establish how patients experience the impact of spondyloarthritis (SpA) on work disability and working life. Methods The survey was performed in 17/20 regions in Italy (1 January to 31 March 2013). A multiple-choice questionnaire was published on the official website of the sponsor - the National Association of Rheumatic Patients (ANMAR) - and hard-copies were distributed at outpatient clinics for rheumatic patients. Results Respondents (n = 770) were of both sexes (56 % men), educated (62 % at high school or more), of working age (75 % aged ≤60 years), and affected by SpA. The most common types diagnosed were ankylosing spondylitis (AS) (39 %) and psoriatic arthri…

MaleAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Adult; Aged; Arthritis Psoriatic; Employment; Female; Humans; Italy; Male; Middle Aged; Self Report; Spondylitis Ankylosing; Surveys and Questionnaires; Absenteeism; Disability Evaluation; Quality of Life; Rheumatology; Immunology and Allergy; ImmunologySettore MED/16 - REUMATOLOGIAWPIAlternative medicinePsoriaticDisability Evaluation0302 clinical medicineSurveys and QuestionnairesAbsenteeismSurveys and QuestionnaireImmunology and Allergy030212 general & internal medicineSurveyAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPIWorking lifeWork disabilityMiddle AgedSpondyloarthritis Survey Absenteeism Presenteeism WPIItalyAbsenteeismFemaleResearch ArticleHumanAdultEmploymentAnkylosingmusculoskeletal diseasesmedicine.medical_specialtyImmunology03 medical and health sciencesQuality of life (healthcare)RheumatologySpondyloarthritismedicineHumansSpondylitis AnkylosingSelf reportAged030203 arthritis & rheumatologyAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Adult; Aged; Arthritis Psoriatic; Employment; Female; Humans; Italy; Male; Middle Aged; Self Report; Spondylitis Ankylosing; Surveys and Questionnaires; Absenteeism; Disability Evaluation; Quality of Life; Immunology and Allergy; Rheumatology; Immunologybusiness.industryArthritisArthritis PsoriaticPresenteeismAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Rheumatology; Immunology; Immunology and AllergyFamily medicinePresenteeismQuality of LifeSelf ReportSpondyloarthritibusinessSpondylitisArthritis Research & Therapy
researchProduct

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

2010

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. ©…

MaleAntibodieReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptRandomized controlled triallawimmune system diseasesOutcome Assessment Health CareMonoclonalImmunology and Allergyskin and connective tissue diseasesAntirheumatic AgentAntibodies MonoclonalAntirheumatic AgentsTreatment OutcomeAntirheumatic AgentsFemalemedicine.drugHumanReceptormusculoskeletal diseasesAdultAnkylosingmedicine.medical_specialtyImmunologyDrug Administration ScheduleOutcome Assessment (Health Care)RheumatologyInternal medicinemedicineHumansSpondylitis AnkylosingSpondylitisSpondylitiAnkylosing spondylitisbusiness.industryTumor Necrosis Factor-alphaAnkylosing spondylitis; Etanercept; Infliximab; Adult; Antibodies Monoclonal; Antirheumatic Agents; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Outcome Assessment (Health Care); Receptors Tumor Necrosis Factor; Spondylitis Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Rheumatology; Immunology; Immunology and Allergymedicine.diseaseInfliximabRheumatologyInfliximabClinical trialAnkylosing spondylitistomatognathic diseasesImmunoglobulin GPhysical therapybusinessTumor Necrosis Factor
researchProduct

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management

2015

MaleAutoantibodies; Blood Coagulation Factor Inhibitors; Female; Humans; Male; Hemophilia A; Immunology and Allergy; HematologyBlood Coagulation Factor InhibitorsHumansImmunology and AllergyBlood Coagulation Factor InhibitorFemaleHematologyRecommendationHemophilia AAutoantibodieHumanAutoantibodies
researchProduct